Articles from GN Corporation Co Ltd

A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS cell therapy has been reported by Indo-Japan physician-scientists. This milestone achievement in regenerative medicine, yielding clinical safety and efficacy, is the first of its kind, wherein a hybrid approach of mixing two groups of autologous buccal epithelial cells, one cultured in 2D and another in 3D in Festigel scaffold were used in the management of urethral stricture; paracrine effect of IGF-1 produced by 2D-cultured cells and engraftment of 3D-Festigel cultured cells, which cover the urethrotomy wound, together repairing the urothelial defect, has been published in Frontiers in Urology. This feat though modest, is a global first in terms of both in vitro tissue engineering and clinical benefits by in vivo healing, restoring the urothelial integrity and is a giant leap for its potential of yielding stricture recurrence-free good quality of life to patients with voiding problems, opined the researchers.

Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA.

Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018.

Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan. IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan. Importantly, the mean survival improved after Nichi BRITE administration.

Urethral stricture affecting men of all ages, with increasing incidence after 55, is a recurring problem despite several treatment options. By transplanting autologous lab-engineered buccal tissue cells (BEES-HAUS), Dr Akio Horiguchi successfully accomplished the first clinical transplantation in Edogawa Hospital, Japan as per Japanese Regenerative Medicine law, and presented in International Meeting Of Reconstructive Urology (IMORU) in Hamburg, Germany. Safety and efficacy clinically, reported earlier by Dr Suryaprakash from India, triggered this tech-transfer feat, spearheaded by GN Corporation.

Harshavardhan Sai Sadineni and Srived Meda of Kasturba Medical College, Manipal, India, won the XVIII Fujio Cup Quiz (FCQ) on Stem cells and Regenerative medicine (RM) in the NCRM NICHE 2023; Sri Ramachandra Institute for Higher Education and Research, India and Institut Teknologi Bandung, Indonesia emerged as runners and joined the team of FCQ elites, a privilege bestowed on those who reach the final stage of the multi-level international contest including a quiz in RM, thereby qualifying to nominate the candidate(s) to Edogawa NICHE Prize, instituted in 2018. The Edogawa NICHE Prize awardee of 2020, Dr John Craig Venter will deliver his lecture at the UHN Ajmera Transplant Center, on the 25th October 2023, in conjunction with the Training Program in Regenerative Medicine (TPRM) at the University of Toronto, co-hosted by German Society for Stem Cell Research (GSZ).

Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging related illnesses, inflammaging, longevity and cancer prognosis. Oral consumption of AFO-202 strain of Aureobasidium pullulans produced Nichi BRITE and N-163 strain produced Neu REFIX together in pre-clinical and clinical studies having safely and beneficially modified NLR, are considered holding potential to help maintain astronauts health during space flight and also to bridge the gap between health span and life span by ‘Me-Byo’ phenomenon as published in Frontiers in Immunology while Neu REFIX standalone yielding enhanced dystrophin, an additional benefit that might help prevent muscle loss during space missions.

Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine medications. Clinical improvements published in IBRO Neuroscience reports, might be the world's first such report, wherein, a safe food supplement, mitigated biomarkers of relevance to muscle dysfunction in DMD without side-effects. Increased plasma dystrophin by 32%, indicating improved blood circulation along with muscle strength improvement, is a breakthrough, unraveling the multipronged potential of Neu-REFIX, which also beneficially reconstituted gut microbiome in DMD, gives hope of improving the quality of life and prolonging the life span of DMD patients, opined Dr. Raghavan, the lead author.